Sanofi (NASDAQ: SNY) has declared today that its BTK inhibitor, Rilzabrutinib, has been awarded Fast Track Designation from FDA. Rilzabrutinib has shown encouraging results in the Phase ½ study and now it is planning to commence Phase III study. Rilzabrutinib has the potential to treat immune thrombocytopenia (ITP).

FTD is a process intended to accelerate the growth and the review of medicines to treat serious diseases. FDA is responsible for granting this to the companies which are engaged in the development of the cure of rare diseases. Immune thrombocytopenia (ITP) is a condition in which a patient has low platelets.

Sanofi (SNY) has seen some recent movement in the market and its common shares finished trading at $50.50 yesterday. People are starting to take interest in SNY as the common shares traded as high as $51.28 and as low as $50.48 in the prior market trading session.

Sanofi (SNY) average trading volume is 1.09M. However, in the prior market trading session Sanofi (SNY) traded 1,068,089 shares. The 1st support level on SNY is $49.69 and the 1st resistance level on SNY is $54.03. SNY 50day moving average is $49.61 and SNY 200 day moving average is $50.46.

Sanofi (SNY) recent performance has been specified by the recent movement in SNY common shares. SNY has performed 1.24% over the past 4 weeks, SNY has performed -1.75% over the past 3 months and SNY has shown 9.26% over the past year. Sanofi (SNY) has a 52 week range of $37.62 to $55.00. Sanofi (SNY) is trading 34.24% from its 52 week low and -8.18% from its 52 week high. Sanofi (SNY) is indicating a 0.17% short float indicating the amount short in the float.

SNY has 2.51B shares outstanding and 2.25B shares in the float. Sanofi (SNY) currently has a market cap of $126.71B and an income of 13.25B. The EPS next quarter for SNY is 0.67 and the forecasted EPS next year is 9.40%. The market cap of Sanofi (SNY) at $126.71B signifies how many People own shares of SNY and is calculated off the last price ($50.50) of SNY and the amount of shares outstanding (2.51B) with Sanofi (SNY).

Sanofi (SNY) has and total debt/equity (mrq) is 39.26. SNY is trading 3.12% above (bullish) its SMA20, 0.82% above (bullish) its SMA50 and 2.45% above (bullish) its SMA200.